Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
01 août 2019 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company...
Geron Enhances Oncology Expertise to Advance Corporate Objectives
18 juil. 2019 16h15 HE
|
Geron Corporation
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky...
Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer
29 mai 2019 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced...
Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
06 mai 2019 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
- Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs - - Enrollment Progressing in Pivotal CONNECT-FX Trial of Zygel in FXS, with Data Expected...
Equillium to Present at Leerink Partners Global Healthcare Conference
21 févr. 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce...
Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
11 févr. 2019 07h00 HE
|
Apellis Pharmaceuticals, Inc.
New designation now includes all PNH patients WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical...
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
02 janv. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
20 déc. 2018 16h01 HE
|
ARCA biopharma, Inc.
Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
19 déc. 2018 08h06 HE
|
Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
12 sept. 2018 09h30 HE
|
FibroGen, Inc
SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...